ADL Amdl,

AMDL Receives Food and Drug Administration Response to Recent Submission TUSTIN, Calif., June 8 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), a developer and marketer of tests for the early detection of cancer and other serious diseases, today announced that its consultant, Diagnostic Oncology Clinical Research Organization, (DOCRO) received a non-substantial equivalence letter from the U.S. FDA. The FDA pointed out several areas of concern in the recent adjunctive submission. AMDL believes that because AMDL has applied for approval of DR-70(R) as an adjunctive test to be used in conjunction with CEA (carcinoembryonic antigen) in monitoring colorectal cancer, substantial equivalence does not apply. The adjunctive submission from DOCRO showed that by using DR-70(R) in conjunction with the CEA (carcinoembryonic antigen) test, which is the standard test for this disease, there is a significant positive gain in sensitivity of 24% for monitoring the progression of the clinical disease status in previously diagnosed colorectal cancer patients as compared to using the CEA test by itself. The CEA test has sensitivity that varies from 40 to 70 percent, according to published literature. DOCRO is setting up a meeting with the FDA and AMDL to discuss the FDA's specific concerns which are necessary to grant marketing approval. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright